CAR T Cell Therapy Market Revenues to exceed USD 15 Billion by 2035 | Roots Analysis

CAR-T cell therapy, amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR T cell therapy, a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. 

Overall, this highly specific and promising form of CAR T therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally.

Key Report Takeaways

§  With more than 800 therapy programs in the clinical phases of development, CAR-T cell therapies have already established a strong foothold in the overall pharmaceutical industry.

§  Further, close to 300 therapies targeting oncological disorders are in the early (pre-clinical and discovery phase) stages of development. CAR T cell therapy companies are developing therapies against several novel targets.

§  Currently, over 210 CAR T cell therapy companies are involved in developing potential treatment options for oncological, non-oncological and other disorders. Additionally, players such as CARgen Therapeutics and Kite Pharma (a Gilead Sciences company) are revolutionizing CAR-T therapies manufacturing, driving impactful advancements in healthcare.

§  Over 10,000 patents related to CAR T cell therapies have been recently filed / granted, demonstrating the continued innovation in CAR T cell therapy market.

§  More than 260 partnerships and collaborations have been inked between several industry / academic stakeholders in order to expedite the development of various pipeline candidates. To fund CAR-T cell therapy development, capital investments worth more than USD 32 billion have been made by various private and public sector investors, in the last few years.

§  According to the cancer data published by the Leukemia and Lymphoma Society in 2023, there were 59,610 new cases of leukemia, along with 89,380 new cases of lymphoma in the US.

§  Based on the regional distribution, North America held 67% market share in 2024 (in terms of revenues generated through sales of approved CAR T cell therapies). Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption.

Competitive Landscape of CAR-T Cell Therapy Market

CAR-T cell therapy is among the most promising domains in the healthcare industry. Currently, over 210 CAR T cell therapy companies are involved in developing potential treatment options for oncological, non-oncological and other disorders.

Additionally, players such as CARgen Therapeutics and Kite Pharma (a Gilead Sciences company) are revolutionizing CAR-T therapies manufacturing, driving impactful advancements in healthcare. In January 2024, Kite Pharma achieves a milestone with the FDA's approval of their advancement in manufacturing process for axicabtagene ciloleucel (Yescarta®), significantly eliminating the median turnaround time.

CAR-T Cell Therapy Market Regional Outlook

Based on the regional distribution, North America held more than 65% market share in 2024 (in terms of revenues generated through sales of approved CAR T cell therapies). Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption.

By 2035, Asia Pacific is likely to capture more than 24% share of the global market share. However, in 2024 Yescarta (Axicabtagene Ciloleucel) became the first CAR T cell therapy to receive approval from NICE to be provided to the patients through NHS. As such, the Asia Pacific market will continue to grow at a healthy CAGR during the forecast period.

Key Companies:

Key companies in CAR-T cell therapies are Autolus, bluebird bio, Bristol Myers Squibb, CARsgen Therapeutics, Cellectis, Gilead Sciences, Innovative Cellular Therapeutics, Noile-Immune Biotech, Novartis, Sinobioway Cell Therapy, Takara Bio, Wellington Zhaotai Therapies.

Market Segments

Based on the research, Roots Analysis has segmented the CAR-T cell therapy Market into Type of Target Antigen, Type of Target Indication, Key Geographical Regions, Sales Forecast of CAR-T cell Therapies and Leading Players.

by Type of Target Antigen

§  CD 19

§  B-cell Maturation Antigen (BCMA)

§  CD 20

§  CD 19/22

§  Other Target Antigens

by Type of Target Indication

§  Acute Lymphoblastic Leukemia

§  Diffuse Large B-cell Lymphoma

§  Follicular Lymphoma

§  Large B-cell Lymphoma

§  Mantle Cell Lymphoma

§  Multiple Myeloma

§  Others

by Key Geographical Regions

§  North America

§  Europe

§  Asia Pacific

§  Latin America

§  Middle East and North Africa

§  Rest of the World

Sales Forecast

§  Approved Therapies

§  Clinical Stage Therapies (Phase II and above)

by Leading Players

§  Gilead Sciences

§  Bristol Myers Squibb

§  Novartis

§  Janssen

§  JW Therapeutics

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: sales@rootsanalysis.com